Jeff Ubben's Inclusive Capital Sells $369 Million in Bayer Stock
By Adria Calatayud
Investment firm Inclusive Capital, founded by activist investor Jeff Ubben, is selling a stake in Bayer for 318 million euros ($369.3 million).
Inclusive Capital sold around 8.5 million shares in the German agricultural and pharmaceutical company, representing a 0.9% stake, according to terms of the sale seen by Dow Jones Newswires. The shares were sold at 37.45 euros each, according to the deal terms. Bayer's shares closed at 38.47 euros on Monday.
Shares in Bayer were down 2.1% at 37.67 euros in European midday trading Tuesday, having fallen as much as 3.7% earlier. The stock is up 56% over the past year.
Bloomberg first reported the stock sale.
Ubben's firm took a stake in Bayer in early 2023 and pushed the company to hire an external candidate as its chief executive.
Bayer appointed Ubben to its supervisory board in 2024 with a mandate until 2028, citing his experience in financial and capital markets.
The Wall Street Journal reported in 2023 that Ubben was shutting down his social investing-focused firm, Inclusive Capital Partners, and that it had begun winding down its funds and returning capital to its limited partners.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
March 24, 2026 08:37 ET (12:37 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States